Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
BOSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc.
Vertex stock rockets to record, boosting market cap by $8 billion
Vertex stock rockets to record, boosting market cap by $8 billion
Vertex Pharmaceuticals Inc.
Shire pens bispecific hemophilia R&D deal with Novimmune
Shire pens bispecific hemophilia R&D deal with Novimmune
As the hemophilia market builds and tensions fray, Shire has signed a new licensing deal targeting bispecific antibodies.
FDA collaborates to promote safety, quality in clinical trials done in India
FDA collaborates to promote safety, quality in clinical trials done in India
After more than 16 hours of travel, we touch down in Mumbai late in the evening and are greeted by a wave of heat and humidity as we exit the airport terminal.
FDA approves Vosevi for Hepatitis C
FDA approves Vosevi for Hepatitis C
The U.
China adds blockbuster drugs to insurance list after price cuts
China adds blockbuster drugs to insurance list after price cuts
SHANGHAI (Reuters) - China will add three dozen new drugs to a list of medicines covered by basic insurance schemes after global pharmaceutical firms agreed to slash prices of blockbuster trea...
FDA approves new treatment to reduce the risk of breast cancer returning
FDA approves new treatment to reduce the risk of breast cancer returning
The U.
27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next five years
27 Phase III and 8 Phase II Alzheimer's drugs on track to launch in next five years
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheimer's pipeline analysis ...
M&As this week: Sanofi, GE Healthcare, Medicure
M&As this week: Sanofi, GE Healthcare, Medicure
Sanofi has announced plans to acquire US-based vaccines biotechnology company, Protein Sciences Corporation.
Deals this week: North China Pharmaceutical, Arena Pharmaceuticals, Enterome Bioscience
Deals this week: North China Pharmaceutical, Arena Pharmaceuticals, Enterome Bioscience
Chinese pharmaceutical company North China Pharmaceutical has announced the completion of a public offering of ten million short-term bonds to raise CNY1bn ($146.
Global health price tag could be $371 billion a year by 2030, WHO says
Global health price tag could be $371 billion a year by 2030, WHO says
LONDON (Reuters) - Meeting life-saving global health targets by 2030 could require investments by donors and national governments of up to $58 per person per year, or $371 billion annually, th...
Pascal Soriot To Remain As Chief Executive Of AstraZeneca
Pascal Soriot To Remain As Chief Executive Of AstraZeneca
LONDON (Alliance News) - Pascal Soriot is to remain as chief executive of AstraZeneca, the FT reported on Friday, scotching two days of rumours that he was leaving to head rival drugmaker Teva...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand